Last update Feb. 12, 2019
A tertiary antimuscarinic amine with actions similar to atropine. Indicated as a urinary antispasmodic in bladder incontinence problems.
Oral administration 1 to 3 times a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data - large volume of distribution and high percentage of protein binding (AEMPS2016, Ortho2008) - make it unlikely that significant quantities will be transferred to breastmilk.
Its very low oral bioavailability (AEMPS2016, Ortho2008, Duchamos 1988) hinders transfer to infant plasma from breastmilk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
Milk production should be monitored, since anticholinergics can reduce milk production.
Possible anticholinergic symptoms (dry mouth, constipation...) in the infant should be monitored.
Expert authors consider the use of this medication to probably be safe during breastfeeding (Brigs 2017, Hale 2017 p 737).
Other similar anticholinergics, such as atropine, are considered by the American Academy of Pediatrics to usually be compatible with breastfeeding.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM